Top 50 Life Science VC (Venture Capital) Funds in United States in December 2024
A list of 50 VC (Venture Capital) funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.Top 50 Life Science VC (Venture Capital) Funds in United States in December 2024
Investor | Life Science United States investments |
---|---|
ARCH Venture Partners | 24 |
SOSV | 21 |
Alexandria Venture Investments | 19 |
Northpond Ventures | 19 |
Novartis Venture Fund | 14 |
RA Capital Management | 14 |
Third Rock Ventures | 13 |
Atlas Venture | 13 |
DCVC | 12 |
Fifty Years | 11 |
Civilization Ventures | 11 |
Hatteras Venture Partners | 11 |
8VC | 11 |
OrbiMed | 10 |
Sahsen Ventures | 10 |
5AM Ventures | 10 |
Andreessen Horowitz | 10 |
MPM Capital | 10 |
Alix Ventures | 10 |
Rev1 Ventures | 9 |
SR One | 9 |
Longwood Fund | 9 |
Google Ventures | 9 |
KdT Ventures | 9 |
Versant Ventures | 9 |
Vivo Capital | 8 |
Playground Global | 8 |
iSelect Fund | 8 |
Cormorant Asset Management | 8 |
Lux Capital | 8 |
The Column Group | 8 |
New Enterprise Associates | 8 |
Apple Tree Partners | 8 |
Illumina Ventures | 7 |
Pear VC | 7 |
Foresite Capital | 7 |
Connecticut Innovations | 7 |
Dolby Family Ventures | 7 |
Horizons Ventures | 7 |
Artis Ventures (AV) | 7 |
Breakout Ventures | 7 |
Flagship Pioneering | 7 |
Roche Venture Fund | 7 |
Mission BioCapital | 6 |
JDRF T1D Fund | 6 |
Canaan Partners | 6 |
RiverVest | 6 |
Alumni Ventures | 6 |
F-Prime Capital | 6 |
Felicis | 6 |
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Canada, France
Portfolio highlights
- Jupiter BioVentures — Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
- Valora Therapeutics — Valora Therapeutics is a biotechnology company that provides engineering of chimeric antibodies .
- Autoimmunity BioSolutions — ABS is developing a next-generation, immuno-corrective therapy to restore normal immune function in a genetically-defined subpopulation of autoimmune disease patients.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
- VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Canada
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
- Synapticure — The era of personalized care is finally coming to ALS. Synapticure will give all ALS patients access to the best care while fueling the advancement of personalized treatments for every type of ALS.
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Marea Therapeutics — Marea Therapeutics is a clinical-stage biotechnology firm that uses the most recent advancements in human genetics to create first-in-class, next-generation medications for cardiometabolic illnesses.
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Q-CTRL — Infrastructure software to power the quantum future
- Radiant — Clean. Portable. Safe. Energy
- Reality Defender — Reality Defender is deepfake detection done right. With billions of visual and audio assets indexed, we offer the most robust deepfake detection available.
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
- BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
- Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.
DIGITAL HEALTH / AI
DIGITAL HEALTH / AI GENE / CELL THERAPIES
NASDAQ: RCKT GENE / CELL THERAPIES
NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS
SYNTHETIC
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, Canada
Portfolio highlights
- Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
- Synaptrix — Synaptrix is a medical device start-up company dedicated to developing and commercializing drug-free pain management solutions for postoperative joint surgery patients. The proprietary NOVABLOC system is a procedure-based solution that delivers a novel type of electrical stimulation. Human feasibili
- AtaCor Medical — AtaCor Medical - Designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
8VC seeks to enable industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Surglogs — Surglogs streamlines and automates the administration of logbooks, medications, supplies, in-services, and drills in healthcare facilities. The outdated pen-and-paper method is replaced with a HIPAA compliant state of the art digital application, complemented with a desktop portal that serves as an administrative dashboard.Surglogs was founded in2015 and headquartered in California, United States.
- Seen Health — We are building a culturally-focused, technology-enabled healthcare organization that integrates comprehensive medical care and social support with a high-touch, interdisciplinary approach. We plan to augment a proven home and community based services model by embracing the unique cultural and healthcare needs of the communities we serve, and empowering our staff with thoughtfully designed technology to scale the highest quality care to many more older adults.
- Workflow — A minimalist collaboration platform for creative teams. Manage tasks, get AI reviews, and share work, all in one place.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
- Lomond Therapeutics — Targeting escape mutations in hematological cancers with first and best in class medicines.
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
- Biotechnology, Health Care, Non Profit
- Funding Round, Series A, Seed
- United States, China, Ghana
Portfolio highlights
- Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
- TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
- Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- xAI — XAI is an AI company that develops a platform to accelerate human scientific discovery. The company primarily focuses on developing advanced AI systems that are truthful, competent, and maximally beneficial for all of humanity. Its mission is to understand the true nature of the universe.
- HappyRobot — Happyrobot is the AI that extracts quantitative data from geospatial imagery with English queries
- Sinatra — Sinatra's AI copilot for e-commerce assists medium and big firms in streamlining operations. through process automation, real-time anomaly detection and analysis, auditing of sales pipelines to increase profitability and cut expenses, and platform integration.
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
- Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
- Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Seed, Series A, Pre-Seed
- United States
Portfolio highlights
- Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
- Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
- Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- United States, Germany
Portfolio highlights
- HubiFi — SaaS Financial Automation & Analysis for High Transaction Businesses
- Myoptechs — Myoptechs, a pediatric ophthalmic medical device startup in the clinical stage, has made advancements in its fund-raising and clinical research program. The company creates innovative soft contact lenses and spectacles that reduce the growth of myopia while offering incredibly clear vision.
- Power to Hydrogen — Power to Hydrogen (P2H2) is simplifying hydrogen. Our technology enables a brighter energy future by solving the technical and economic challenges that come with producing hydrogen. Our AEM-based, electrolysis technology produces high pressure, high efficiency hydrogen from renewable energy with lower cost materials thancompeting electrolyzers. This technology can reduce the total cost of hydrogen to enable clean transportation, store energy efficiently, and decarbonize industrial processes. In addition to low-cost, high-pressure hydrogen production, the technology can produce high-pressure oxygen and be used reversibly to produce electricity. Both services can create additional revenue streams to make the total cost of hydrogen $1/kg.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Nomic — Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels.It allowsnanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Italy
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Roboflow — With just a few dozen example images, you can train a working, state-of-the-art computer vision model in less than 24 hours
- Synapticure — The era of personalized care is finally coming to ALS. Synapticure will give all ALS patients access to the best care while fueling the advancement of personalized treatments for every type of ALS.
- Rox — Transform your sales process with Rox. Leverage AI agents to boost productivity, gain actionable insights, and close deals faster.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- 858 Therapeutics — 858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Pep2Tango Therapeutics — Pep2Tango Therapeutics is a biotechnology company that offers superior unimolecular multi-receptor drugs for obesity and related disorders.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts.
The firm operates as a multi-fund investment platform, covering growth equity, private
equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series C, Series A
- United States, China, United Kingdom
Portfolio highlights
- 35Pharma — 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
- Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
- Serán Bioscience — Leading pharmaceutical innovator offering tailored drug solutions with comprehensive analytical and manufacturing services for biotech and pharma.
Playground is an early-stage investment firm that helps old and new investors and entrepreneurs working at the intersection of bits, atoms, and AI. It focuses on investment, innovation, connected hardware, artificial intelligence, and robotics.
Show more
Investment focus
- Software, Robotics, Artificial Intelligence
- Series A, Seed, Series B
- United States, Canada, France
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
- Biotechnology, Health Care, Agriculture
- Seed, Series A, Series B
- United States, Australia
Portfolio highlights
- Holobiome — Holobiome is an owner and operator of a therapeutic company intended to treat diseases of the enteric and central nervous systems. The company's platform delivers microbiome-based therapeutics to patients and the marketplace by treating depression, anxiety, and other mental health problems including our metabolism and the immune response,enabling patients to recover quickly from their diseases easily without any pain and suffering.Holobiome was established in 2015 and is based in Cambridge, Massachusetts.
- MEND — Mend is the scientifically proven way to heal and enhance your body faster.
- Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Switzerland
Portfolio highlights
- enGene — enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expressionlevels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
- OnKure Therapeutics — OnKure Therapeutics - Writing the Next Chapter in Precision Medicines for Patients With Cancer
- Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
- Enveda Biosciences — Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California.
- Physical Intelligence — Physical Intelligence is bringing general-purpose AI into the physical world.
The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Nura Bio — Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders.
- Circle Pharma — Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
- NGM Biopharmaceuticals — Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series B, Series A, Series C
- United States, India, China
Portfolio highlights
- Sana — Sana is an AI company building the next generation of knowledge tools. Designed and engineered in Stockholm, Sweden.
- Fastino — Fastino provides enterprise AI developers with high-performance, task-optimized language models built to scale.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Canada, United Kingdom
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, France
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.
- Predicta Biosciences — Our blood-based approach unlocks true precision medicine.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Seed, Series A, Pre-Seed
- United States, Brazil, Colombia
Portfolio highlights
- Advex AI — Advex AI assists the world's largest manufacturers in cutting costs and increasing productivity by producing highly dependable computer vision models in hours.
- Cardless — Cardless is a credit card company. They help brands launch custom cobrand credit card products. They handle the program creation, card underwriting, lending, issuance, and top-notch customer service, while brands focus on delivering rewards truly valuable to their superfan cardholders.Cardless was founded in February 2019 by Michael Spelfogel andScott Kazmierowicz (ex-Stanford CS / Data Science, ex-Lyft, ex-Visa, ex-Goldman) and is backed by top VCs including Accomplice, Greycroft, Clocktower Ventures, as well as founders of Plastiq, SeatGeek, Flatiron Health, and FiveStars
- Federato — Insurers can no longer afford to underutilize data. RiskOps means more precise + productive underwriting live in only 8 weeks... yes, seriously. Thinking yet?
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- Spear Bio — Successive Proximity Extension Amplification Reaction (SPEAR) technology from Spear Bio enables ultra-sensitive biomarker detection using ultra-small samples.
- Chimagen Biosciences — Chimagen Biosciences is a company that is creating a novel class of multi-functional monoclonal antibodies for cancer therapy.
- Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- AmpUp — Commercial electric vehicle (EV) charging network solutions made simple for everyone. Easily manage and analyze EV charging data from a single dashboard.
- Air Company — We are a carbon utilization company working with industries to create planetary change, taking Earth's excess CO2 and converting it into carbon-negative alcohols and fuels.
- Nimbus Power Systems — Nimbus builds a cleaner world through design and integration of zero-emission fuel cell systems for heavy-duty markets.
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Series B
- United States, Austria, Israel
Portfolio highlights
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
- Esper Satellite Imagery — Welcome to Esper Satellite Imagery. Enjoy your Stay.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Software
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
- Medal — Gamers live here. Medal is the best way to record, clip, edit, and share your gaming clips and videos. Clip, Edit, Share, and Relive your gaming moments.
- ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Series A, Series B, Seed
- United States, India, Germany
Portfolio highlights
- Eko Health — At Eko every digital stethoscope from Eko comes with smart disease detection capabilities to help healthcare professionals confidently identify and diagnose heart and lung disease during physical exams.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.
Show more
Investment focus
- Biotechnology, Life Science, Therapeutics
- Seed, Series B, Series A
- United States
Portfolio highlights
- CytoVale — Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California, United States.
- TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
- Copernic Catalysts — Mantel is developing the material solution to carbon capture
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Canada, United Kingdom
Portfolio highlights
- Mirai Bio — Mirai Bio has developed an open platform powered by AI to address the main drawbacks and manufacturing to develop the future of genetic medicine.
- Inari — Inari is a biotech seed company that embraces diversity in every aspect of its business to drive innovation and help build a new food system. Our technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of seed. We are always innovating, pushing the boundaries of what’s possible.Our SEEDesign platform is our point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach.
- Prologue Medicines — Prologue is systematically discovering the therapeutic potential of secreted proteins tuned through millennia of natural evolution to rapidly create powerful new medicines.
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Spain
Portfolio highlights
- DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, Switzerland
Portfolio highlights
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
- Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.
- Jupiter BioVentures — Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, France, Italy
Portfolio highlights
- vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
- SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
- Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Israel
Portfolio highlights
- Glooko — Glooko's digital health and connected care solutions improve health outcomes for people with diabetes and related chronic conditions.
- Nivoda — Nivoda provides jewellery businesses with a simple solution to strengthen profits, increase efficiency and accelerate growth with its B2B diamond marketplace. Designed to save you time and money whilst giving you access to the world’s diamond supply at the best prices with zero inventory risk, Nivoda is trusted by thousands of retailers all overthe globe.
- Enterpret — All customer feedback categorized automatically, combined with advanced analytics capabilities that ensure no customer pain goes unnoticed.
RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States
Portfolio highlights
- Biolinq — Introducing a revolutionary platform for metabolic health.
- Engrail Therapeutics — Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
- Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.
Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- PrivacyHawk — PrivacyHawk is a Personal Data Protection service that makes opting out, unsubscribing, and deleting your data from thousands of companies easy.
- Fortera — 8% of global greenhouse emissions are caused by cement manufacturing, accounting for more than 3.5 billion tons of CO2 produced each year. Fortera addresses CO2 emissions directly from the kiln.
- Trestle — Trestle helps construction organizations streamline the vendor contracting and procurement process with integration, smart tools, and use data that's currently going uncollected to reduce risks in future contracts.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Series C
- United States, United Kingdom, China
Portfolio highlights
- Teleo — Teleo is revolutionizing material moving industries by turning heavy equipment into supervised autonomous machines.
- Zenflow — Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need.
- Lighthouse — Lighthouse is a commercial platform for the travel & hospitality industry. The company transforms complexity into confidence by providing actionable market insights, business intelligence, and pricing tools that maximize revenue growth. Lighthouse was previously known as OTA Insight.
Backing founders building iconic companies that transcend boundaries
Show more
Investment focus
- Software, SaaS, Health Care
- Series A, Seed, Series B
- United States, Canada, Germany
Portfolio highlights
- Tines — Tines is an enterprise automation platform designed to help security and ops teams automate manual workloads. With 1,000+ template options for common security actions, Tines is power and simplicity through direct integration with your existing tools. The company was founded in 2018 and is headquartered in Dublin.
- Midi Health — Expert care for women 40+. Made for midlife. Delivered by experienced clinicians. Covered by insurance. Book a visit today.
- Edia Learning — Edia is an EdTech platform for 6-12 Math that ensures superior state test outcomes.
Investors by industry
Biotech
Proptech
Gaming
FinTech
Health Care
Community
Google
Marketplace
Climate
Consumer
Artificial intelligence
Impact
Energy
Hardware
EdTech
Sustainability
Venture Capital
Clean Energy
B2B
Real Estate
Publishing
Payments
Big Data
Retail
Organic Food
Web3
Education
Finance
Food and Beverage
Video Games
Infrastructure
Financial Services
Photography
Beauty
Medical
Wellness
Social Media
Social Network
Android
Construction
Art
Local
Legal
Digital Media
Manufacturing
eSports
Sports
Music
Mobile
Internet
Enterprise Software
Franchise
Email
Travel
Mobile Advertising
Biotechnology
Recruiting
Hospitality
Fitness
Platforms
Cannabis
Medical Device
Social
Automotive
Crowdfunding
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Film
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Social Impact
Restaurants
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Canada
New Zealand
Ireland
United States
Qatar
Saudi Arabia
Spain
Sri Lanka
China
Middle East
Africa
Indonesia
Europe
Armenia
Singapore
Oceania
Brazil
Japan
South Africa
Vietnam
LATAM
Asia
Denmark
Costa Rica
Bermuda
Egypt
Croatia
Gibraltar
Algeria
Estonia
Ecuador
Greece
Chile
Bulgaria
Ethiopia
Hong Kong
Faroe Islands
France
Ghana
Czech Republic
Hungary
Georgia
Belgium
Finland
Bahrain
Belarus
Belize
Barbados
Lebanon
Mali
Liberia
Malta
Liechtenstein
Malaysia
Italy
Puerto Rico
Tunisia
Uganda
Panama
Sierra Leone
Senegal
San Marino
Uzbekistan
Seychelles
Togo
El Salvador
Rwanda
Russian Federation
Tanzania
Ukraine
Zimbabwe
Uruguay
Serbia
Taiwan
Venezuela
Tajikistan
Sweden
Turkey
Poland
Thailand
Myanmar
Zambia
Portugal
Slovenia
Dominican Republic
Mauritius
Nicaragua
Azerbaijan
Iraq
Iceland
Bahamas
Namibia
Nigeria
Philippines
United Arab Emirates
Jamaica
Honduras
Lithuania
Bolivia
Israel
Isle of Man
Luxembourg
Jersey
Norway
Morocco
Albania
Pakistan
Mexico
Peru
Kuwait
Bangladesh
Argentina
Grenada
Jordan
Romania
Kenya
Kazakhstan
Cayman Islands
Cambodia
Cameroon
Cyprus
Latvia
Oman
Austria
Switzerland
Colombia
Marshall Islands
Guatemala
VC (Venture Capital) Funds in United States by industry
Transportation
Enterprise
FinTech
Consumer
Biotech
Health Care
Climate
Impact
Energy
Sustainability
Proptech
SaaS
Marketplace
Community
Artificial intelligence
Gaming
Venture Capital
Crowdfunding
Retail
Financial Services
LGBT
Oil and Gas
Film
Publishing
Cryptocurrency
Education
Payments
Food and Beverage
Wine And Spirits
Video Games
Restaurants
Medical
Franchise
Wellness
EdTech
Email
Hardware
Social Media
Manufacturing
Digital Media
Celebrity
Art
Theatre
Blockchain
Android
Mobile
Google
Social Impact
Legal
Software
Non Profit
Local
Finance
Enterprise Software
Sports
eSports
CleanTech
Hospitality
Automotive
InsurTech
Travel
Biotechnology
Cannabis
Platforms
Mobile Advertising
Real Estate
Fashion
Infrastructure
Social
Web3
Life Science
Photography
Sporting Goods
Big Data
Clean Energy
Construction
Mobile Apps
Medical Device
B2B
Social Network
Fitness
Renewable Energy
Music
Internet
Beauty
Facebook
Agriculture (agtech)
Media (entertainment)
Organic Food
Recruiting